<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00560755</url>
  </required_header>
  <id_info>
    <org_study_id>V221-037</org_study_id>
    <secondary_id>MRV01C</secondary_id>
    <secondary_id>2007-002438-12</secondary_id>
    <nct_id>NCT00560755</nct_id>
  </id_info>
  <brief_title>Safety Study of ProQuad® rHA in Infants (V221-037)</brief_title>
  <official_title>An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured With Recombinant Human Albumin (rHA) When Administered to Children in Their Second Year of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: To describe the safety profile of a second dose of ProQuad® manufactured
      with recombinant human albumin (rHA) when administered to children in their second year of
      life.

      Secondary objectives: To describe the safety profile of a first dose of ProQuad® manufactured
      with rHA when administered to children in their second year of life.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2007</start_date>
  <completion_date type="Actual">November 24, 2008</completion_date>
  <primary_completion_date type="Actual">November 24, 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing an Adverse Event (AE) After ProQuad® Dose 2</measure>
    <time_frame>Up to Day 70 (up to 28 days after ProQuad® Dose 2)</time_frame>
    <description>The percentage of participants experiencing an AE(s) for up to 28 days after the second ProQuad® injection was determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing a Vaccine-related AE After ProQuad® Dose 2</measure>
    <time_frame>Up to Day 70 (up to 28 days after ProQuad® Dose 2)</time_frame>
    <description>The percentage of participants experiencing a vaccine-related AEs for up to 28 days after the second ProQuad® injection was determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing a Solicited Injection-site AE After ProQuad® Dose 2</measure>
    <time_frame>Up to Day 46 (for 4 days following ProQuad® Dose 2)</time_frame>
    <description>The solicited injection-site AEs erythema, swelling, and pain were monitored for 4 days after administration of ProQuad® Dose 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing a Unsolicited Injection-site AE After ProQuad® Dose 2</measure>
    <time_frame>Up to Day 70 (up to 28 days after ProQuad® Dose 2)</time_frame>
    <description>The percentage of participants experiencing a unsolicited injection-site AE(s) were monitored for up to 28 days after the second ProQuad® injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing a Injection-site Rash of Interest AE After ProQuad® Dose 2</measure>
    <time_frame>Up to Day 70 (up to 28 days after ProQuad® Dose 2)</time_frame>
    <description>Injection-site rashes of interest, including measles-like, rubella-like, and vesicular, were monitored for up to 28 days after the second ProQuad® injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing a Systemic AE After ProQuad® Dose 2</measure>
    <time_frame>Up to Day 70 (up to 28 days after ProQuad® Dose 2)</time_frame>
    <description>Systemic AEs were monitored for up to 28 days after the second ProQuad® injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing a Vaccine-related Systemic AE After ProQuad® Dose 2</measure>
    <time_frame>Up to Day 70 (up to 28 days after ProQuad® Dose 2)</time_frame>
    <description>Vaccine-related systemic AEs were monitored for up to 28 days after the second ProQuad® injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing a Non-injection-site Rash of Interest AE After ProQuad® Dose 2</measure>
    <time_frame>Up to Day 70 (up to 28 days after ProQuad® Dose 2)</time_frame>
    <description>Non-injection-site rashes of interest, including measles-like, rubella-like, varicella-like, and zoster-like rashes, were monitored for up to 28 days after the second ProQuad® injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing a Mumps-like Illness After ProQuad® Dose 2</measure>
    <time_frame>Up to Day 70 (up to 28 days after ProQuad® Dose 2)</time_frame>
    <description>The percentage of participants experiencing a mumps-like illness for up to 28 days after the second ProQuad® injection was determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing a Serious AE (SAE) After ProQuad® Dose 2</measure>
    <time_frame>Up to Day 84 (up to 42 days after ProQuad® Dose 2)</time_frame>
    <description>Serious AEs ere defined as any untoward consequence that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, is a congenital anomaly/birth defect, or is any other medically important event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing a Vaccine-related SAE After ProQuad® Dose 2</measure>
    <time_frame>Up to Day 84 (up to 42 days after ProQuad® Dose 2)</time_frame>
    <description>Vaccine-related SAEs were defined as any untoward consequence that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, is a congenital anomaly/birth defect, or is any other medically important event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing a Solicited Injection-site AE After ProQuad® Dose 1</measure>
    <time_frame>From Day 1 to Day 4 (for 4 days following ProQuad® Dose 1)</time_frame>
    <description>The solicited injection-site AEs erythema, swelling, and pain were monitored for 4 days after administration of ProQuad® Dose 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing a Unsolicited Injection-site AE After ProQuad® Dose 1</measure>
    <time_frame>Up to Day 28 (28 days after ProQuad® Dose 1)</time_frame>
    <description>Unsolicited injection-site AEs were monitored for up to 28 days after the first ProQuad® injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥ 1 Rectal Temperature Reading ≥ 38.0° C After ProQuad® Dose 1</measure>
    <time_frame>Up to Day 28 (28 days after ProQuad® Dose 1)</time_frame>
    <description>The percentage of participants with at least 1 rectal temperature reading ≥ 38.0° C was determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing a Systemic AE After ProQuad® Dose 1</measure>
    <time_frame>Up to Day 28 (28 days after ProQuad® Dose 1)</time_frame>
    <description>Systemic AEs were monitored for up to 28 days after the first ProQuad® injection.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3388</enrollment>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>ProQuad®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ProQuad®</intervention_name>
    <description>ProQuad® manufactured with recombinant human albumin (rHA) is an investigational combined attenuated live virus vaccine for vaccination against measles, mumps, rubella and varicella viruses.</description>
    <arm_group_label>ProQuad®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subject of either gender,

          -  Age from 12 to 22 months,

          -  Negative clinical history of infection with measles, mumps, rubella, varicella or
             zoster,

          -  Informed consent form signed by the parent(s) or by legal representative

          -  Parent(s) or legal representative able to attend all schedule visits with the subject
             and to understand and comply with the study procedures

        Exclusion Criteria:

          -  Recent (≤ 3 days) history of febrile illness

          -  Prior receipt of measles, mumps, rubella and/or varicella vaccination, either alone or
             in any combination

          -  Recent (≤ 30 days) exposure to measles, mumps, rubella, varicella or zoster

          -  Prior known sensitivity/allergy to any component of the vaccine

          -  Severe chronic disease,

          -  Blood dyscrasias, leukaemia, lymphomas of any type, or other malignant neoplasms
             affecting the haematopoietic and lymphatic system

          -  Any severe thrombocytopenia or any other coagulation disorder that would
             contraindicate intramuscular injection

          -  Humoral or cellular immunodeficiency,

          -  Current immunosuppressive therapy

          -  Family history of congenital or hereditary immunodeficiency

          -  Hereditary problems of fructose intolerance

          -  Known personal history of encephalopathy, seizure disorder or progressive, evolving or
             unstable neurological condition,

          -  Known active tuberculosis

          -  Recent (≤ 2 days) tuberculin test or scheduled tuberculin test through Visit 3

          -  Receipt of immunoglobulins or blood-derived products in the past 150 days

          -  Receipt of an inactivated vaccine in the past 14 days

          -  Receipt of a live vaccine in the past 28 days

          -  Any medical condition which, in the opinion of the investigator, might interfere with
             the evaluation of study objectives

          -  Participation in another clinical study in the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>22 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne FIQUET, MD</last_name>
    <role>Study Director</role>
    <affiliation>MCM Vaccines B.V.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2007</study_first_submitted>
  <study_first_submitted_qc>November 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2007</study_first_posted>
  <results_first_submitted>September 18, 2017</results_first_submitted>
  <results_first_submitted_qc>September 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 17, 2017</results_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention of: measles, mumps, rubella and varicella</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Measles</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Rubella</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy pediatric participants were enrolled at 84 study centers in 7 European countries.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ProQuad®</title>
          <description>Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3388">Vaccinated (at least one ProQuad® dose)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>ProQuad® Dose 1 and Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="3346"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3328"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ProQuad®</title>
          <description>Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3388"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.6" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1650"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing an Adverse Event (AE) After ProQuad® Dose 2</title>
        <description>The percentage of participants experiencing an AE(s) for up to 28 days after the second ProQuad® injection was determined.</description>
        <time_frame>Up to Day 70 (up to 28 days after ProQuad® Dose 2)</time_frame>
        <population>All participants who received the second ProQuad® dose and had safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad®</title>
            <description>Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing an Adverse Event (AE) After ProQuad® Dose 2</title>
          <description>The percentage of participants experiencing an AE(s) for up to 28 days after the second ProQuad® injection was determined.</description>
          <population>All participants who received the second ProQuad® dose and had safety follow-up data available are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.66" lower_limit="55.96" upper_limit="59.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing a Vaccine-related AE After ProQuad® Dose 2</title>
        <description>The percentage of participants experiencing a vaccine-related AEs for up to 28 days after the second ProQuad® injection was determined.</description>
        <time_frame>Up to Day 70 (up to 28 days after ProQuad® Dose 2)</time_frame>
        <population>All participants who received the second ProQuad® dose and had safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad®</title>
            <description>Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing a Vaccine-related AE After ProQuad® Dose 2</title>
          <description>The percentage of participants experiencing a vaccine-related AEs for up to 28 days after the second ProQuad® injection was determined.</description>
          <population>All participants who received the second ProQuad® dose and had safety follow-up data available are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.77" lower_limit="40.09" upper_limit="43.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing a Solicited Injection-site AE After ProQuad® Dose 2</title>
        <description>The solicited injection-site AEs erythema, swelling, and pain were monitored for 4 days after administration of ProQuad® Dose 2.</description>
        <time_frame>Up to Day 46 (for 4 days following ProQuad® Dose 2)</time_frame>
        <population>All participants who received the second ProQuad® dose and had safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad®</title>
            <description>Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing a Solicited Injection-site AE After ProQuad® Dose 2</title>
          <description>The solicited injection-site AEs erythema, swelling, and pain were monitored for 4 days after administration of ProQuad® Dose 2.</description>
          <population>All participants who received the second ProQuad® dose and had safety follow-up data available are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection-site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.46" lower_limit="28.90" upper_limit="32.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.23" lower_limit="12.09" upper_limit="14.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.49" lower_limit="10.43" upper_limit="12.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing a Unsolicited Injection-site AE After ProQuad® Dose 2</title>
        <description>The percentage of participants experiencing a unsolicited injection-site AE(s) were monitored for up to 28 days after the second ProQuad® injection.</description>
        <time_frame>Up to Day 70 (up to 28 days after ProQuad® Dose 2)</time_frame>
        <population>All participants who received the second ProQuad® dose and had safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad®</title>
            <description>Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing a Unsolicited Injection-site AE After ProQuad® Dose 2</title>
          <description>The percentage of participants experiencing a unsolicited injection-site AE(s) were monitored for up to 28 days after the second ProQuad® injection.</description>
          <population>All participants who received the second ProQuad® dose and had safety follow-up data available are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" lower_limit="1.24" upper_limit="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing a Injection-site Rash of Interest AE After ProQuad® Dose 2</title>
        <description>Injection-site rashes of interest, including measles-like, rubella-like, and vesicular, were monitored for up to 28 days after the second ProQuad® injection.</description>
        <time_frame>Up to Day 70 (up to 28 days after ProQuad® Dose 2)</time_frame>
        <population>All participants who received the second ProQuad® dose and had safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad®</title>
            <description>Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing a Injection-site Rash of Interest AE After ProQuad® Dose 2</title>
          <description>Injection-site rashes of interest, including measles-like, rubella-like, and vesicular, were monitored for up to 28 days after the second ProQuad® injection.</description>
          <population>All participants who received the second ProQuad® dose and had safety follow-up data available are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="0.00" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing a Systemic AE After ProQuad® Dose 2</title>
        <description>Systemic AEs were monitored for up to 28 days after the second ProQuad® injection.</description>
        <time_frame>Up to Day 70 (up to 28 days after ProQuad® Dose 2)</time_frame>
        <population>All participants who received the second ProQuad® dose and had safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad®</title>
            <description>Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing a Systemic AE After ProQuad® Dose 2</title>
          <description>Systemic AEs were monitored for up to 28 days after the second ProQuad® injection.</description>
          <population>All participants who received the second ProQuad® dose and had safety follow-up data available are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.42" lower_limit="38.76" upper_limit="42.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing a Vaccine-related Systemic AE After ProQuad® Dose 2</title>
        <description>Vaccine-related systemic AEs were monitored for up to 28 days after the second ProQuad® injection.</description>
        <time_frame>Up to Day 70 (up to 28 days after ProQuad® Dose 2)</time_frame>
        <population>All participants who received the second ProQuad® dose and had safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad®</title>
            <description>Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing a Vaccine-related Systemic AE After ProQuad® Dose 2</title>
          <description>Vaccine-related systemic AEs were monitored for up to 28 days after the second ProQuad® injection.</description>
          <population>All participants who received the second ProQuad® dose and had safety follow-up data available are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.44" lower_limit="12.30" upper_limit="14.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing a Non-injection-site Rash of Interest AE After ProQuad® Dose 2</title>
        <description>Non-injection-site rashes of interest, including measles-like, rubella-like, varicella-like, and zoster-like rashes, were monitored for up to 28 days after the second ProQuad® injection.</description>
        <time_frame>Up to Day 70 (up to 28 days after ProQuad® Dose 2)</time_frame>
        <population>All participants who received the second ProQuad® dose and had safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad®</title>
            <description>Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing a Non-injection-site Rash of Interest AE After ProQuad® Dose 2</title>
          <description>Non-injection-site rashes of interest, including measles-like, rubella-like, varicella-like, and zoster-like rashes, were monitored for up to 28 days after the second ProQuad® injection.</description>
          <population>All participants who received the second ProQuad® dose and had safety follow-up data available are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Measles-like rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" lower_limit="1.22" upper_limit="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella-like rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" lower_limit="0.34" upper_limit="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella-like rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" lower_limit="0.39" upper_limit="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zoster-like rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="0.00" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing a Mumps-like Illness After ProQuad® Dose 2</title>
        <description>The percentage of participants experiencing a mumps-like illness for up to 28 days after the second ProQuad® injection was determined.</description>
        <time_frame>Up to Day 70 (up to 28 days after ProQuad® Dose 2)</time_frame>
        <population>All participants who received the second ProQuad® dose and had safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad®</title>
            <description>Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing a Mumps-like Illness After ProQuad® Dose 2</title>
          <description>The percentage of participants experiencing a mumps-like illness for up to 28 days after the second ProQuad® injection was determined.</description>
          <population>All participants who received the second ProQuad® dose and had safety follow-up data available are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="0.00" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing a Serious AE (SAE) After ProQuad® Dose 2</title>
        <description>Serious AEs ere defined as any untoward consequence that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, is a congenital anomaly/birth defect, or is any other medically important event.</description>
        <time_frame>Up to Day 84 (up to 42 days after ProQuad® Dose 2)</time_frame>
        <population>All participants who received the first ProQuad® dose and had safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad®</title>
            <description>Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing a Serious AE (SAE) After ProQuad® Dose 2</title>
          <description>Serious AEs ere defined as any untoward consequence that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, is a congenital anomaly/birth defect, or is any other medically important event.</description>
          <population>All participants who received the first ProQuad® dose and had safety follow-up data available are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.41" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing a Vaccine-related SAE After ProQuad® Dose 2</title>
        <description>Vaccine-related SAEs were defined as any untoward consequence that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, is a congenital anomaly/birth defect, or is any other medically important event.</description>
        <time_frame>Up to Day 84 (up to 42 days after ProQuad® Dose 2)</time_frame>
        <population>All participants who received the first ProQuad® dose and had safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad®</title>
            <description>Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing a Vaccine-related SAE After ProQuad® Dose 2</title>
          <description>Vaccine-related SAEs were defined as any untoward consequence that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, is a congenital anomaly/birth defect, or is any other medically important event.</description>
          <population>All participants who received the first ProQuad® dose and had safety follow-up data available are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" lower_limit="0.08" upper_limit="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing a Solicited Injection-site AE After ProQuad® Dose 1</title>
        <description>The solicited injection-site AEs erythema, swelling, and pain were monitored for 4 days after administration of ProQuad® Dose 1.</description>
        <time_frame>From Day 1 to Day 4 (for 4 days following ProQuad® Dose 1)</time_frame>
        <population>All participants who received the first ProQuad® dose and had safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad®</title>
            <description>Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing a Solicited Injection-site AE After ProQuad® Dose 1</title>
          <description>The solicited injection-site AEs erythema, swelling, and pain were monitored for 4 days after administration of ProQuad® Dose 1.</description>
          <population>All participants who received the first ProQuad® dose and had safety follow-up data available are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection-site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.31" lower_limit="13.14" upper_limit="15.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.57" lower_limit="4.82" upper_limit="6.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.31" lower_limit="9.30" upper_limit="11.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing a Unsolicited Injection-site AE After ProQuad® Dose 1</title>
        <description>Unsolicited injection-site AEs were monitored for up to 28 days after the first ProQuad® injection.</description>
        <time_frame>Up to Day 28 (28 days after ProQuad® Dose 1)</time_frame>
        <population>All participants who received the first ProQuad® dose and had safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad®</title>
            <description>Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing a Unsolicited Injection-site AE After ProQuad® Dose 1</title>
          <description>Unsolicited injection-site AEs were monitored for up to 28 days after the first ProQuad® injection.</description>
          <population>All participants who received the first ProQuad® dose and had safety follow-up data available are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.43" lower_limit="6.57" upper_limit="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥ 1 Rectal Temperature Reading ≥ 38.0° C After ProQuad® Dose 1</title>
        <description>The percentage of participants with at least 1 rectal temperature reading ≥ 38.0° C was determined.</description>
        <time_frame>Up to Day 28 (28 days after ProQuad® Dose 1)</time_frame>
        <population>All participants who received the first ProQuad® dose and had safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad®</title>
            <description>Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥ 1 Rectal Temperature Reading ≥ 38.0° C After ProQuad® Dose 1</title>
          <description>The percentage of participants with at least 1 rectal temperature reading ≥ 38.0° C was determined.</description>
          <population>All participants who received the first ProQuad® dose and had safety follow-up data available are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.10" lower_limit="0.85" upper_limit="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing a Systemic AE After ProQuad® Dose 1</title>
        <description>Systemic AEs were monitored for up to 28 days after the first ProQuad® injection.</description>
        <time_frame>Up to Day 28 (28 days after ProQuad® Dose 1)</time_frame>
        <population>All participants who received the first ProQuad® dose and had safety follow-up data available are included.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad®</title>
            <description>Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing a Systemic AE After ProQuad® Dose 1</title>
          <description>Systemic AEs were monitored for up to 28 days after the first ProQuad® injection.</description>
          <population>All participants who received the first ProQuad® dose and had safety follow-up data available are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.10" lower_limit="62.45" upper_limit="65.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>ProQuad® Dose 1: Up to Day 28 ProQuad® Dose 2: Up to Day 84 (up to 42 days after Dose 2)</time_frame>
      <desc>Participants who were vaccinated and have safety follow-up data are included. Data are presented separately for each post-dose monitoring period.</desc>
      <group_list>
        <group group_id="E1">
          <title>ProQuad® Arm: Dose 2</title>
          <description>Healthy infants (12 to 22 months of age) received ProQuad® Dose 2 on Day 28 to Day 42.</description>
        </group>
        <group group_id="E2">
          <title>ProQuad® Arm: Dose 1</title>
          <description>Healthy infants (12 to 22 months of age) received ProQuad® Dose 1 on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="3342"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="3376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3342"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3342"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3342"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3342"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3342"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3342"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Acute tonsilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Gastroenteritis Norwalk virus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3342"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Pseudocroup</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Tonsilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3342"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3342"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3342"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3342"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3342"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Respiratory fume inhalation disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Tongue injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus insulin-dependent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3342"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3342"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="3342"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep terror</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3342"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3376"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1507" subjects_at_risk="3342"/>
                <counts group_id="E2" subjects_affected="2057" subjects_at_risk="3376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Diarrhoea</sub_title>
                <counts group_id="E1" events="120" subjects_affected="111" subjects_at_risk="3342"/>
                <counts group_id="E2" events="207" subjects_affected="191" subjects_at_risk="3376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="1032" subjects_affected="1024" subjects_at_risk="3342"/>
                <counts group_id="E2" events="664" subjects_affected="628" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="385" subjects_affected="384" subjects_at_risk="3342"/>
                <counts group_id="E2" events="352" subjects_affected="351" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="449" subjects_affected="447" subjects_at_risk="3342"/>
                <counts group_id="E2" events="228" subjects_affected="225" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="591" subjects_affected="526" subjects_at_risk="3342"/>
                <counts group_id="E2" events="1274" subjects_affected="1122" subjects_at_risk="3376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="184" subjects_affected="174" subjects_at_risk="3342"/>
                <counts group_id="E2" events="198" subjects_affected="185" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Rhinits</sub_title>
                <counts group_id="E1" events="148" subjects_affected="142" subjects_at_risk="3342"/>
                <counts group_id="E2" events="198" subjects_affected="181" subjects_at_risk="3376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Cough</sub_title>
                <counts group_id="E1" events="178" subjects_affected="166" subjects_at_risk="3342"/>
                <counts group_id="E2" events="211" subjects_affected="199" subjects_at_risk="3376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Rash</sub_title>
                <counts group_id="E1" events="103" subjects_affected="101" subjects_at_risk="3342"/>
                <counts group_id="E2" events="235" subjects_affected="226" subjects_at_risk="3376"/>
              </event>
              <event>
                <sub_title vocab="MedDRA v. 10.0">Rash mobilliform</sub_title>
                <counts group_id="E1" events="55" subjects_affected="54" subjects_at_risk="3342"/>
                <counts group_id="E2" events="236" subjects_affected="232" subjects_at_risk="3376"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sanofi Pasteur MSD shall have sixty days to review these documents and may refuse to give its consent in part or whole for confidential reasons (including but not limited to intellectual property rights, whether patentable or not).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

